Procaps Group

About Us

Procaps Group, S.A. ("Procaps Group") (NASDAQ: PROC) is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,300 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over the counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

Press Realease

Procaps Announces ESG Commitments and Initiatives with Inaugural Report

MIAMI and BARRANQUILLA, Colombia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced the completion of its inaugural 2021 ESG Annual Report, a comprehensive overview of environmental, social and governance metrics and corresponding strategies and initiatives for ESG priorities.

October 11, 2022 8:00am EDT

Read more View PDF

Pharmaceutical Group
dedicated to delivering
health and nutrition

We employ over 5,300 people across 13 countries

Our products reach 
50+ markets

Virtual Tour